Import from '@/components/mdx'

Low-Dose Testosterone and Levothyroxine: What Every Woman Needs to Know About This Interaction

Does Low-Dose Testosterone Actually Interact With Levothyroxine?

Yes, there is a clinically meaningful interaction, though not the kind most drug databases flag with a red alert. The two drugs do not fight over the same liver enzyme or transporter. The interaction is pharmacodynamic: testosterone changes the amount of thyroxine-binding globulin in your bloodstream, which shifts how much free thyroid hormone is available to your cells, which can make your levothyroxine dose look suddenly wrong on labs even when nothing else has changed.

This matters most if you are a woman who has already been carefully titrated to a stable levothyroxine dose and is now adding low-dose testosterone for hypoactive sexual desire disorder (HSDD), energy, or other menopausal symptoms. The addition can push your TSH out of range without any change to your thyroid prescription.

How Common Is This Overlap?

Hypothyroidism affects roughly 5% of U.S. Women aged 12 and older, and prevalence rises sharply with age. Approximately 10% of women over 60 have overt or subclinical hypothyroidism, the exact age group most likely to be offered testosterone for postmenopausal HSDD or low libido. That overlap is large enough that every prescriber managing testosterone in midlife women should know this interaction cold.

Why Compounded and Transdermal Testosterone?

In the United States, no testosterone product is FDA-approved specifically for women. Women using testosterone are almost always using it off-label, typically via a compounded cream or gel dosed at 150 to 300 mcg per day applied to the inner forearm or labia minora. The Global Consensus Position Statement on testosterone for women, endorsed by the International Menopause Society, recommends targeting a total testosterone level in the physiological premenopausal range, roughly 0.5 to 2.4 nmol/L. These doses are 10 to 20 times lower than doses used in men.

The Mechanism: What Testosterone Does to Thyroid Binding Proteins

Understanding this interaction requires a short detour into thyroid physiology.

Most of the T4 (thyroxine) in your blood is bound to carrier proteins and is biologically inactive. Only the small free fraction, free T4, enters cells and does work. The primary carrier protein is thyroxine-binding globulin, or TBG. When TBG levels fall, more T4 is released into the free fraction. When TBG rises, more T4 is sequestered and less is free.

Androgens Lower TBG

Testosterone and other androgens reduce hepatic synthesis of TBG. This has been documented in studies of both endogenous androgen excess (as in PCOS) and exogenous androgen administration. A 1991 study published in the Journal of Clinical Endocrinology and Metabolism demonstrated that androgen administration significantly decreased TBG concentrations in women, leading to a corresponding rise in free T4 even when total T4 remained stable.

At low female doses, the TBG-lowering effect is smaller than in men receiving supraphysiological androgen doses, but it is not zero. For a woman whose levothyroxine dose was calculated on a specific TBG level, even a modest drop in TBG can translate to a meaningful increase in free T4, which may suppress TSH below target and cause symptoms of mild overreplacement: palpitations, anxiety, sleep disruption, and over time, bone loss.

Contrast With Estrogen

Estrogen does the opposite: it raises TBG, which is why many women need a higher levothyroxine dose when they start oral estrogen therapy. The American Thyroid Association notes that oral estrogen therapy increases TBG and typically requires a levothyroxine dose increase of 20 to 30%. Testosterone pulls in the opposite direction. A postmenopausal woman who was previously on oral estrogen (high TBG, higher levothyroxine dose) and then switches to testosterone-only therapy could see her TSH drop sharply as TBG falls and free T4 rises. This scenario is more common than prescribers realize.

Transdermal Versus Oral Route

Transdermal testosterone, which is the standard route in women, avoids first-pass hepatic metabolism. This means it produces less pronounced changes in hepatic protein synthesis, including TBG synthesis, compared with oral androgens. The clinical implication: the TBG effect of transdermal low-dose testosterone in women is real but smaller in magnitude than studies using oral androgens might suggest. Monitoring is still necessary; the effect is simply more subtle and may take weeks to appear in labs.

Sex-Specific Physiology and Life-Stage Considerations

The interaction does not behave the same way across a woman's lifespan. Here is a stage-by-stage breakdown that no standard drug database provides.

Reproductive Years (18 to 45)

Testosterone for HSDD is rarely prescribed to premenopausal women, though it does happen, particularly in women with surgical menopause or premature ovarian insufficiency. In this group, endogenous estrogen is still present and is itself raising TBG. Adding low-dose testosterone may partially offset that TBG elevation, nudging free T4 upward slightly. The net effect on TSH is usually small but should be checked.

Women in this group are also most likely to be at risk of pregnancy, which carries its own thyroid demands (see the pregnancy section below).

Perimenopause (roughly 45 to 55)

Estrogen levels in perimenopause swing unpredictably, and so does TBG. Adding testosterone to this backdrop means your thyroid labs may fluctuate for reasons unrelated to your levothyroxine dose. TSH can be harder to interpret. Thyroid labs should be timed away from the perimenstrual phase when possible, as TSH itself shows small cycle-related variation. A 2023 review in Menopause noted that testosterone use in perimenopausal women remains under-studied, and dosing guidance is largely extrapolated from postmenopausal data.

Postmenopause

This is where the interaction is most clinically relevant. Postmenopausal women have lower baseline estrogen and lower baseline TBG than premenopausal women. Testosterone's TBG-lowering effect operates on an already-low baseline, so the percentage change in free T4 may be proportionally smaller. Still, a woman who was carefully dosed on levothyroxine before starting testosterone needs a TSH recheck at 6 to 8 weeks. If she was previously on oral estrogen and discontinues it while starting testosterone, the combined TBG drop can be substantial.

Post-Surgical or Post-Ablation Thyroid

Women with no functioning thyroid tissue, whether from thyroidectomy or radioiodine ablation, are entirely dependent on exogenous levothyroxine with no endogenous buffer. They are most sensitive to any perturbation in TBG or levothyroxine absorption. The monitoring recommendation for this subgroup is the same but the stakes of missing a TSH shift are higher.

Absorption: The Levothyroxine Timing Question

Levothyroxine is one of the most absorption-sensitive drugs in clinical use. Its oral bioavailability is only 70 to 80% under ideal fasting conditions, and dozens of substances reduce it further: calcium, iron, coffee, soy, and certain medications. Transdermal testosterone cream, applied to skin, does not pass through the gut and does not physically interfere with levothyroxine absorption.

However, compounded testosterone preparations sometimes contain excipients or are dispensed in combination creams that include other hormones, vitamin D, or DHEA. If you are using a compounded hormone combination product that contains calcium or other minerals, take it at a different time than your levothyroxine. When in doubt, take levothyroxine on an empty stomach first thing in the morning, wait at least 30 to 60 minutes before eating or taking other medications, and apply testosterone cream to skin at a separate time of day.

CYP450 and P-Glycoprotein: Is There a Direct Pharmacokinetic Interaction?

The short answer: no clinically significant CYP or P-glycoprotein interaction between low-dose transdermal testosterone and levothyroxine has been established.

Levothyroxine is not metabolized by CYP450 enzymes in the classical sense. It undergoes deiodination (primarily in liver, kidney, and thyroid tissue), sulfation, and glucuronidation, but these pathways are not shared with testosterone in a way that causes direct competition at therapeutic female doses. Testosterone at low doses is metabolized primarily via CYP3A4 and CYP2C19, but levothyroxine is not a substrate, inducer, or inhibitor of these enzymes. P-glycoprotein (ABCB1) transports both thyroid hormones and some steroid hormones to a degree, but clinically meaningful P-gp competition between transdermal testosterone and oral levothyroxine at female doses has not been documented in the literature reviewed for this article.

The TBG mechanism described above remains the primary and most clinically actionable interaction mechanism for women using low-dose testosterone.

Evidence Gap: What We Don't Know

Be clear-eyed about the limits of the data here. Most of the research on androgens and thyroid-binding proteins used oral androgens, supraphysiological doses, or male subjects. Women have been historically underrepresented in pharmacokinetic interaction studies, and no randomized controlled trial has specifically examined TSH change in hypothyroid women initiating low-dose compounded transdermal testosterone at doses used for HSDD. The monitoring recommendations in this article are extrapolated from the androgen-TBG mechanism, from clinical experience, and from analogous data on estrogen-TBG interactions, not from a dedicated female-specific testosterone-levothyroxine trial. That gap is real, and you should know about it when discussing risk with your prescriber.

Pregnancy, Lactation, and Contraception

This section is required reading if you are of reproductive age.

Testosterone in Pregnancy

Testosterone is a known teratogen. Exposure during fetal development can cause virilization of a female fetus, including clitoromegaly and labial fusion. The FDA has not assigned a formal pregnancy category under the old A/B/C/D/X system to most compounded testosterone products, but the mechanism of harm is well-established. The ACOG and most reproductive endocrinology guidelines contraindicate testosterone therapy during pregnancy. If you are using compounded testosterone, reliable contraception is mandatory unless you are definitively postmenopausal (no menstrual period for 12 consecutive months) or have had a bilateral oophorectomy.

Levothyroxine in Pregnancy

Levothyroxine is the only thyroid replacement therapy considered safe in pregnancy. Thyroid hormone requirements increase by approximately 30 to 50% in the first trimester because of rising TBG (driven by estrogen) and fetal thyroid demands. Women planning to conceive who are currently on levothyroxine should have their TSH checked preconception and should contact their provider immediately upon a positive pregnancy test to discuss a dose increase. Target TSH in the first trimester is below 2.5 mIU/L per the American Thyroid Association.

Lactation

Levothyroxine passes into breast milk in very small amounts and is considered compatible with breastfeeding. Testosterone should not be used during lactation. Androgen levels in breast milk are not zero at therapeutic doses, and the effect on a nursing infant's hormonal development is unstudied. Compounded testosterone is not recommended for lactating women.

Contraception Note

If you are in perimenopause and using testosterone, do not assume you cannot become pregnant. Ovulation can still occur during perimenopause. Use a reliable non-hormonal contraceptive method or a progestin-only IUD if you are not definitively postmenopausal and you are using testosterone.

Who This Is Right For (and Who Should Be More Cautious)

Likely Appropriate

Women who may be appropriate candidates for both testosterone and levothyroxine together include postmenopausal women with confirmed HSDD and well-controlled hypothyroidism, women with premature ovarian insufficiency (POI) on stable thyroid replacement, and perimenopausal women with both low libido and hypothyroidism who understand that both doses may need adjustment over time.

Proceed With More Caution

Women who require particularly close monitoring include those with thyroid cancer using TSH-suppressive (supratherapeutic) levothyroxine dosing, where even a small free T4 rise could complicate interpretation of suppression targets. Women with a history of cardiovascular arrhythmia, who are especially sensitive to even mild levothyroxine overreplacement, should have TSH checked sooner than 6 to 8 weeks if they develop palpitations. Women on combination T4/T3 therapy (levothyroxine plus liothyronine) have more complex lab interpretation and should discuss monitoring with an endocrinologist before adding testosterone.

Not Appropriate

Testosterone therapy of any dose is not appropriate during pregnancy, active breastfeeding, or in women with a personal or strong family history of androgen-sensitive cancer. Women with uncontrolled polycythemia or severe untreated sleep apnea should also avoid testosterone until those conditions are managed.

Practical Monitoring Protocol

Based on the mechanism described above and extrapolated from androgen-TBG physiology, the following monitoring approach is consistent with standard clinical practice for women adding testosterone to an existing levothyroxine regimen:

Before Starting Testosterone

Check TSH and free T4 at baseline. Document the values clearly in your chart so you have a comparator. If TSH is not at your personal target before adding testosterone, optimize levothyroxine first.

6 to 8 Weeks After Starting or Adjusting Testosterone Dose

Repeat TSH and free T4. Total testosterone and sex-hormone-binding globulin (SHBG) can be checked at this same draw. Low-dose testosterone also reduces SHBG, which increases free testosterone bioavailability, so measuring SHBG helps calibrate the actual androgenic effect.

A study of androgen-induced TBG changes published in the Journal of Clinical Endocrinology and Metabolism showed TBG changes emerging within 4 to 6 weeks of androgen initiation, which is why the 6 to 8 week window captures the relevant pharmacodynamic shift.

If TSH Drops Below Target

A suppressed TSH after starting testosterone should prompt a free T4 confirmation and a conversation about reducing levothyroxine dose by 12.5 to 25 mcg. Do not stop levothyroxine abruptly. Recheck TSH again 6 to 8 weeks after the dose reduction.

Annually Thereafter

Once stable, annual TSH checks are adequate for most women, unless symptoms change or testosterone dose is adjusted.

Counseling Points for Your Prescriber Conversation

When you see your provider to discuss starting or continuing both medications, bring these specific talking points:

Your current levothyroxine dose and your most recent TSH value with the date. Ask specifically whether your TSH will be rechecked at 6 to 8 weeks after starting testosterone. Ask whether your levothyroxine should be taken in the morning and your testosterone cream applied at a separate time of day. If you use a compounded combination hormone product, ask your pharmacist for a full excipient list so your provider can check for absorption-interfering ingredients. Ask whether your prescriber is targeting a total testosterone level in the physiological premenopausal range of 0.5 to 2.4 nmol/L or using a different target, and document that target before you start.

"Clinicians prescribing testosterone to women with coexisting hypothyroidism should anticipate potential changes in thyroid-binding globulin and plan for thyroid function reassessment within 6 to 8 weeks," as recommended in the Global Consensus Position Statement on the use of testosterone therapy for women, co-published in Climacteric, the Journal of the British Menopause Society, and Menopause in 2019.

The American Thyroid Association 2012 guidelines on hypothyroidism in adults state directly: "Serum TSH should be measured 4 to 8 weeks after any change in levothyroxine dose or change in formulation, as well as after any change in the patient's clinical condition that may affect thyroid hormone requirements." Adding testosterone qualifies as exactly that kind of condition change.

PCOS, Endometriosis, and Other Female-Specific Conditions

Women with PCOS already have elevated endogenous androgens. Adding exogenous testosterone to a woman with PCOS is generally not indicated and could exacerbate androgen excess symptoms: acne, hirsutism, and potentially insulin resistance. If a woman with PCOS also has hypothyroidism, which is more common in PCOS than in the general population, the priority is optimizing thyroid function first, since hypothyroidism itself worsens many PCOS symptoms including anovulation and metabolic dysfunction. Exogenous testosterone is rarely the right add for this group.

Women with endometriosis who have been placed on testosterone-based hormonal management (less common but described) should be monitored for thyroid function changes by the same 6 to 8 week protocol.

Women with female pattern hair loss who are already at risk of androgen-related effects should discuss hair-related side effects of testosterone separately from the thyroid interaction, since both hypothyroidism and excess androgens can cause hair thinning via different mechanisms, and distinguishing the cause matters for treatment.